Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis

INTRODUCTION: Current consensus recommendations suggest that patients with antiphospholipid antibodies (APLA) are at high risk of recurrent arterial or venous thromboembolism (VTE) despite warfarin administered to achieve an international normalized ratio (INR) of 2.0 to 3.0. These recommendations have been called into question by three recently reported studies. METHODS: We sought to determine the current "best practice" for the prevention of …